KR20170043655A - 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 - Google Patents

멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 Download PDF

Info

Publication number: KR20170043655A
Authority: KR; South Korea
Prior art keywords: melanin; composition; eye; disease; corneal
Prior art date: 2014-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020177008116A

Other languages

English (en)

Korean (ko)

Inventor

아르투로 솔리스 헤레라

Original Assignee

아르투로 솔리스 헤레라

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-09

Filing date

2015-09-08

Publication date

2017-04-21

2015-09-08 Application filed by 아르투로 솔리스 헤레라 filed Critical 아르투로 솔리스 헤레라

2015-09-08 Priority to KR1020187035645A priority Critical patent/KR102256185B1/ko

2017-04-21 Publication of KR20170043655A publication Critical patent/KR20170043655A/ko

Status Ceased legal-status Critical Current

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- Y10S514/912—

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020177008116A 2014-09-09 2015-09-08 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 Ceased KR20170043655A (ko)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
KR1020187035645A KR102256185B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462048013P	2014-09-09	2014-09-09
US62/048,013		2014-09-09
PCT/IB2015/001570 WO2016038441A1 (fr)	2014-09-09	2015-09-08	Procédés de traitement et de prévention de maladies, de troubles et d'affections oculaires avec de la mélanine et des analogues, des précurseurs, et des dérivés de mélanine

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020187035645A Division KR102256185B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법

Publications (1)

Publication Number	Publication Date
KR20170043655A true KR20170043655A (ko)	2017-04-21

Family

ID=55458388

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
KR1020177008116A Ceased KR20170043655A (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
KR1020187035645A Active KR102256185B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
KR1020207003591A Active KR102299096B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
KR1020187035645A Active KR102256185B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
KR1020207003591A Active KR102299096B1 (ko)	2014-09-09	2015-09-08	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법

Country Status (10)

Country	Link
US (1)	US10220021B2 (fr)
EP (1)	EP3190887B1 (fr)
JP (1)	JP6499290B2 (fr)
KR (3)	KR20170043655A (fr)
CN (1)	CN107072203B (fr)
CA (1)	CA2960583C (fr)
ES (1)	ES2855076T3 (fr)
MX (1)	MX369060B (fr)
RU (1)	RU2672564C2 (fr)
WO (1)	WO2016038441A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6716130B2 (ja) *	2016-07-04	2020-07-01	学校法人中部大学	抗アレルギー剤
WO2021225657A2 (fr) *	2020-02-06	2021-11-11	Avisa Myko, Inc.	Protection contre un rayonnement ionisant
CN111419793A (zh) *	2020-04-29	2020-07-17	上海紫河生物科技有限公司	一种含富勒烯及其衍生物的滴眼液及其制备方法
WO2023151788A1 (fr) *	2022-02-09	2023-08-17	Katairo Gmbh	Mélanine pour le traitement de maladies associées à la lipofuscine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5210076A (en) *	1988-09-13	1993-05-11	Berliner David L	Methods of treating Parkinson's disease using melanin
US20030096735A1 (en) *	2001-09-28	2003-05-22	D'amato Robert J.	Use of melanin for inhibition of angiogenesis and macular degeneration
CA2341903A1 (fr) *	1998-08-21	2000-03-02	The Children's Medical Center Corporation	Utilisation de melanine pour inhiber l'angiogenese et la degenerescence maculaire
WO2000040262A1 (fr) *	1999-01-05	2000-07-13	The Flinders University Of South Australia	Nouveaux agents et methodes pour le traitement et le diagnostic de troubles oculaires
WO2003060131A1 (fr) *	2002-01-09	2003-07-24	Suntory Limited	Transferase gn-t de sucre presentant un effet angiogenique
CN101228297A (zh)	2005-06-09	2008-07-23	阿图罗·索利斯埃雷拉	使用黑色素或其类质、源质、衍化物作为主要电解质将水分解成氢和氧的光电化学方法
EA016227B1 (ru) *	2005-11-29	2012-03-30	Смитклайн Бичем Корпорейшн	Способ лечения офтальмологических неоваскулярных расстройств
WO2007102724A2 (fr) *	2006-03-08	2007-09-13	Solis Herrera Arturo	Effets de la propriété photoélectrolysante des mélanines, de leurs analogues et dérivés, sur la biologie cellulaire, et leur utilisation à des fins diverses
EP2801359A3 (fr)	2006-05-08	2015-05-06	Arturo Solis Herrera	Utilisation de nicotine pour le traitement de la septicémie chez l'homme causée par des antibiotiques
EP2310008A4 (fr) *	2008-07-09	2014-03-05	Aspreva Internat Ltd	Solutions de l'acide mycophenolique de sodium a ph specifiques pour le traitement de troubles oculaires
KR101271593B1 (ko) *	2010-07-16	2013-06-11	대우제약 주식회사	마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물

2015
- 2015-09-08 MX MX2017003060A patent/MX369060B/es active IP Right Grant
- 2015-09-08 KR KR1020177008116A patent/KR20170043655A/ko not_active Ceased
- 2015-09-08 WO PCT/IB2015/001570 patent/WO2016038441A1/fr not_active Ceased
- 2015-09-08 KR KR1020187035645A patent/KR102256185B1/ko active Active
- 2015-09-08 US US15/509,532 patent/US10220021B2/en active Active
- 2015-09-08 JP JP2017532221A patent/JP6499290B2/ja active Active
- 2015-09-08 ES ES15839968T patent/ES2855076T3/es active Active
- 2015-09-08 EP EP15839968.3A patent/EP3190887B1/fr active Active
- 2015-09-08 CN CN201580048315.6A patent/CN107072203B/zh active Active
- 2015-09-08 KR KR1020207003591A patent/KR102299096B1/ko active Active
- 2015-09-08 CA CA2960583A patent/CA2960583C/fr active Active
- 2015-09-08 RU RU2017111579A patent/RU2672564C2/ru active

Also Published As

Publication number	Publication date
JP2017527622A (ja)	2017-09-21
US10220021B2 (en)	2019-03-05
RU2017111579A (ru)	2018-10-10
RU2672564C2 (ru)	2018-11-16
EP3190887A1 (fr)	2017-07-19
JP6499290B2 (ja)	2019-04-10
RU2017111579A3 (fr)	2018-10-10
KR20190005218A (ko)	2019-01-15
MX2017003060A (es)	2017-11-17
KR102299096B1 (ko)	2021-09-07
CA2960583C (fr)	2019-01-15
KR20200015857A (ko)	2020-02-12
CA2960583A1 (fr)	2016-03-17
CN107072203A (zh)	2017-08-18
WO2016038441A1 (fr)	2016-03-17
KR102256185B1 (ko)	2021-05-26
US20170296511A1 (en)	2017-10-19
EP3190887A4 (fr)	2018-04-25
EP3190887B1 (fr)	2020-12-09
CN107072203B (zh)	2020-07-03
ES2855076T3 (es)	2021-09-23
MX369060B (es)	2019-10-28

Legal Events

Date	Code	Title	Description
2017-03-24	A201	Request for examination
2017-03-24	AMND	Amendment
2017-03-24	PA0105	International application	Patent event date: 20170324 Patent event code: PA01051R01D Comment text: International Patent Application
2017-03-24	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20170324 Comment text: Request for Examination of Application
2017-04-21	PG1501	Laying open of application
2018-01-14	E902	Notification of reason for refusal
2018-01-14	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20180114 Patent event code: PE09021S01D
2018-04-16	AMND	Amendment
2018-08-20	E601	Decision to refuse application
2018-08-20	PE0601	Decision on rejection of patent	Patent event date: 20180820 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20180114 Comment text: Notification of reason for refusal Patent event code: PE06011S01I
2018-08-20	X091	Application refused [patent]
2018-09-20	AMND	Amendment
2018-09-20	PX0901	Re-examination	Patent event code: PX09011S01I Patent event date: 20180820 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20180416 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20170324 Comment text: Amendment to Specification, etc.
2018-10-07	PX0601	Decision of rejection after re-examination	Comment text: Decision to Refuse Application Patent event code: PX06014S01D Patent event date: 20181007 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20180920 Comment text: Decision to Refuse Application Patent event code: PX06011S01I Patent event date: 20180820 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20180416 Comment text: Notification of reason for refusal Patent event code: PX06013S01I Patent event date: 20180114 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20170324
2018-10-07	X601	Decision of rejection after re-examination
2018-12-07	A107	Divisional application of patent
2018-12-07	PA0104	Divisional application for international application	Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20181207

Publication	Publication Date	Title
US8455016B2 (en)	2013-06-04	Treatment for meibomian gland dysfunction or obstruction
AU2005260090B2 (en)	2008-06-05	Lubricant for the ocular surface
KR102256185B1 (ko)	2021-05-26	멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
AU2014229371B2 (en)	2018-05-10	Compositions for use in treating eye disorders using dipyridamole
US10973758B2 (en)	2021-04-13	Methods of eye treatment using therapeutic compositions containing dipyridamole
US20140275124A1 (en)	2014-09-18	Methods for treating eye disorders using dipyridamole
Shao et al.	2026	Sustained Ocular Antioxidant Therapy With Thiolated Catalase for Intervention of Corneal Injuries and Atopic Conjunctivitis
Memarzadeh et al.	2004	Corneal and conjunctival toxicity from hydrogen peroxide: a patient with chronic self-induced injury
RU2504372C1 (ru)	2014-01-20	Глазные капли
HK1234605B (en)	2021-04-09	Methods for treating and preventing ocular diseases, disorders, and conditions with melanin
HK1234605A1 (en)	2018-02-23	Methods for treating and preventing ocular diseases, disorders, and conditions with melanin
JP7197112B2 (ja)	2022-12-27	水泡性角膜症治療用医薬組成物
RU2733392C1 (ru)	2020-10-01	Комбинированное офтальмологическое средство
RU2575558C1 (ru)	2016-02-20	Фармацевтическая композиция в виде геля для лечения метаболических поражений тканей глаза
CN118319945A (zh)	2024-07-12	一种可降低眼睛氧化应激反应的洗眼液及其制备方法
RU2506086C1 (ru)	2014-02-10	Глазные капли, обладающие противовоспалительным и антибактериальным действием
UA102957U (uk)	2015-11-25	Спосіб лікування первинної відкритокутової глаукоми
ZA200607607B (en)	2008-05-28	Lubricant for the ocular surface